Heidelberg Pharma FY26 H1 net loss narrows to EUR 3.4 million; revenue and other income rises 84% to EUR 9.2 million

• Heidelberg Pharma posted H1 2026 revenue and other income of EUR 9.2 million, up 84%, as net loss narrowed to EUR 3.4 million.
• Revenue more than doubled to EUR 7.4 million, while operating expenses fell 32% to EUR 12.3 million.
• Cash and cash equivalents climbed to EUR 24.9 million, supported by a USD 20 million upfront payment that extends liquidity into mid-2027.
• HDP-101 Phase I dose escalation in multiple myeloma was completed; Phase IIa dosing started at the RP2D with 16 patients treated so far.
• Outlook reaffirmed for FY 2026 revenue and other income of EUR 11-15 million, operating loss of EUR 13-17 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heidelberg Pharma AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2365936_de) on July 15, 2026, and is solely responsible for the information contained therein.